{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:46:28Z","timestamp":1791906388482,"version":"4.3.4"},"reference-count":153,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025,3,28]]},"DOI":"10.3960\/jslrt.24069","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T18:13:42Z","timestamp":1743099222000},"page":"1-16","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding"],"prefix":"10.3960","volume":"65","author":[{"given":"Kana","family":"Sakamoto","sequence":"first","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan,"},{"name":"Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan,"},{"name":"Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan,"},{"name":"Clinical Pathology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Bueno C, Almeida J, Lucio P <i>et al.<\/i> Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies. Haematologica. 2004; 89: 58-69."},{"key":"2","unstructured":"2 Ng AP, Lade S, Rutherford T <i>et al.<\/i> Primary cutaneous CD4+\/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases. Haematologica. 2006; 91: 143-144."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018; 73: 21-23.","DOI":"10.1016\/j.leukres.2018.08.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004; 15: 1097-1108.","DOI":"10.1093\/annonc\/mdh268"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Facchetti F, Cigognetti M, Fisogni S <i>et al.<\/i> Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016; 29: 98-111.","DOI":"10.1038\/modpathol.2015.145"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Sakamoto K, Katayama R, Asaka R <i>et al.<\/i> Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 2018; 32: 2590-2603.","DOI":"10.1038\/s41375-018-0154-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016; 174: 188-202.","DOI":"10.1111\/bjh.14146"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Herling M, Jones D. CD4+\/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007; 127: 687-700.","DOI":"10.1309\/FY6PK436NBK0RYD4"},{"key":"9","unstructured":"9 Gattei V, Carbone A, Marotta G <i>et al.<\/i> Expression of natural killer (NK) antigens in malignant histiocytosis and a subset of acute myelomonocytic leukaemias. Bone Marrow Transplant. 1989; 4: 22."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Tauchi T, Ohyashiki K, Ohyashiki JH <i>et al.<\/i> CD4+ and CD56+ acute monoblastic leukemia. Am J Hematol. 1990; 34: 228-229.","DOI":"10.1002\/ajh.2830340315"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Brody JP, Allen S, Schulman P <i>et al.<\/i> Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer. 1995; 75: 2474-2483.","DOI":"10.1002\/1097-0142(19950515)75:10<2474::AID-CNCR2820751013>3.0.CO;2-Y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Adachi M, Maeda K, Takekawa M <i>et al.<\/i> High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994; 47: 278-282.","DOI":"10.1002\/ajh.2830470406"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Petrella T, Bagot M, Willemze R <i>et al.<\/i> Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005; 123: 662-675.","DOI":"10.1309\/GJWNPD8HU5MAJ837"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Reimer P, R\u00fcdiger T, Kraemer D <i>et al.<\/i> What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003; 32: 637-646.","DOI":"10.1038\/sj.bmt.1704215"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia\/lymphoma: towards a well defined entity? Br J Haematol. 2007; 136: 539-548.","DOI":"10.1111\/j.1365-2141.2006.06458.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kameoka J, Ichinohasama R, Tanaka M <i>et al.<\/i> A cutaneous agranular CD2- CD4+ CD56+ \u201clymphoma\u201d: report of two cases and review of the literature. Am J Clin Pathol. 1998; 110: 478-488.","DOI":"10.1093\/ajcp\/110.4.478"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Petrella T, Dalac S, Maynadi\u00e9 M <i>et al.<\/i> CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Fran\u00e7ais d\u2019Etude des Lymphomes Cutan\u00e9s (GFELC). Am J Surg Pathol. 1999; 23: 137-146.","DOI":"10.1097\/00000478-199902000-00001"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Petrella T, Comeau MR, Maynadi\u00e9 M <i>et al.<\/i> \u2018Agranular CD4+ CD56+ hematodermic neoplasm\u2019 (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002; 26: 852-862.","DOI":"10.1097\/00000478-200207000-00003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 L\u00facio P, Parreira A, Orfao A. CD123hi dendritic cell lymphoma: an unusual case of non-Hodgkin lymphoma. Ann Intern Med. 1999; 131: 549-550.","DOI":"10.7326\/0003-4819-131-7-199910050-00035"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Kimura S, Kakazu N, Kuroda J <i>et al.<\/i> Agranular CD4+CD56+ blastic natural killer leukemia\/lymphoma. Ann Hematol. 2001; 80: 228-231.","DOI":"10.1007\/s002770000257"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Bayerl MG, Rakozy CK, Mohamed AN <i>et al.<\/i> Blastic natural killer cell lymphoma\/leukemia: a report of seven cases. Am J Clin Pathol. 2002; 117: 41-50.","DOI":"10.1309\/UUXV-YRL8-GXP7-HR4H"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 2003; 101: 5007-5009.","DOI":"10.1182\/blood-2002-10-3297"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Jaye DL, Geigerman CM, Herling M <i>et al.<\/i> Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol. 2006; 19: 1555-1562.","DOI":"10.1038\/modpathol.3800679"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Marafioti T, Paterson JC, Ballabio E <i>et al.<\/i> Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008; 111: 3778-3792.","DOI":"10.1182\/blood-2007-10-117531"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Dijkman R, van Doorn R, Szuhai K <i>et al.<\/i> Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007; 109: 1720-1727.","DOI":"10.1182\/blood-2006-04-018143"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Chaperot L, Bendriss N, Manches O <i>et al.<\/i> Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001; 97: 3210-3217.","DOI":"10.1182\/blood.V97.10.3210"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Chaperot L, Perrot I, Jacob MC <i>et al.<\/i> Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol. 2004; 34: 418-426.","DOI":"10.1002\/eji.200324531"},{"key":"28","unstructured":"28 Swerdlow SH, Campo E, Harris NL, <i>et al.<\/i> WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008."},{"key":"29","unstructured":"29 Swerdlow SH, Campo E, Harris NL, <i>et al.<\/i> WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC; 2017."},{"key":"30","unstructured":"30 WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. 5th ed, vol. 11, Lyon, International Agency for Research on Cancer, 2024."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Leroux D, Mugneret F, Callanan M <i>et al.<\/i> CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique. Blood. 2002; 99: 4154-4159.","DOI":"10.1182\/blood.V99.11.4154"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Tang Z, Li Y, Wang W <i>et al.<\/i> Genomic aberrations involving 12p\/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res. 2018; 73: 86-94.","DOI":"10.1016\/j.leukres.2018.09.006"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Emadali A, Hoghoughi N, Duley S <i>et al.<\/i> Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016; 127: 3040-3053.","DOI":"10.1182\/blood-2015-09-671040"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Jardin F, Callanan M, Penther D <i>et al.<\/i> Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1\/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia. 2009; 23: 698-707.","DOI":"10.1038\/leu.2008.359"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Wiesner T, Obenauf AC, Cota C <i>et al.<\/i> Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest Dermatol. 2010; 130: 1152-1157.","DOI":"10.1038\/jid.2009.369"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Lucioni M, Novara F, Fiandrino G <i>et al.<\/i> Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood. 2011; 118: 4591-4594.","DOI":"10.1182\/blood-2011-03-337501"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Sakamoto K, Takeuchi K. Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm: Chromosomal Rearrangements and DNA Copy-Number Alterations. Hematol Oncol Clin North Am. 2020; 34: 523-538.","DOI":"10.1016\/j.hoc.2020.01.003"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Stenzinger A, Endris V, Pfarr N <i>et al.<\/i> Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget. 2014; 5: 6404-6413.","DOI":"10.18632\/oncotarget.2223"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Renosi F, Callanan M, Lefebvre C. Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells. Cancers (Basel). 2022; 14: 4132.","DOI":"10.3390\/cancers14174132"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Pagano L, Zinzani PL, Pileri S <i>et al.<\/i> Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel. HemaSphere. 2023; 7: e841.","DOI":"10.1097\/HS9.0000000000000841"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Jardin F, Ruminy P, Parmentier F <i>et al.<\/i> TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2011; 153: 413-416.","DOI":"10.1111\/j.1365-2141.2010.08556.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Alayed K, Patel KP, Konoplev S <i>et al.<\/i> TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013; 88: 1055-1061.","DOI":"10.1002\/ajh.23567"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Menezes J, Acquadro F, Wiseman M <i>et al.<\/i> Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014; 28: 823-829.","DOI":"10.1038\/leu.2013.283"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Togami K, Chung SS, Madan V <i>et al.<\/i> Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discov. 2022; 12: 522-541.","DOI":"10.1158\/2159-8290.CD-20-1513"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Sapienza MR, Abate F, Melle F <i>et al.<\/i> Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica. 2019; 104: 729-737.","DOI":"10.3324\/haematol.2018.202093"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Renosi F, Roggy A, Giguelay A <i>et al.<\/i> Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Adv. 2021; 5: 1540-1551.","DOI":"10.1182\/bloodadvances.2020003359"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Summerer I, Walter W, Meggendorfer M <i>et al.<\/i> Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing. Leuk Lymphoma. 2021; 62: 2543-2546.","DOI":"10.1080\/10428194.2021.1924372"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Yin CC, Pemmaraju N, You MJ <i>et al.<\/i> Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2021; 13: 5888.","DOI":"10.3390\/cancers13235888"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Khanlari M, Yin CC, Takahashi K <i>et al.<\/i> Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022; 36: 1343-1350.","DOI":"10.1038\/s41375-022-01538-9"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 K\u00fcnstner A, Schwarting J, Witte HM <i>et al.<\/i> Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm. Blood Cancer J. 2022; 12: 101.","DOI":"10.1038\/s41408-022-00699-1"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Griffin GK, Booth CAG, Togami K <i>et al.<\/i> Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature. 2023; 618: 834-841.","DOI":"10.1038\/s41586-023-06156-8"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Sapienza MR, Fuligni F, Agostinelli C <i>et al.<\/i> Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014; 28: 1606-1616.","DOI":"10.1038\/leu.2014.64"},{"key":"53","unstructured":"53 Pemmaraju N, Kantarjian H. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol. 2023; 21: 257-264."},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Pemmaraju N, Kantarjian H, Sweet K <i>et al.<\/i>: position on standards of care and areas of need. Blood. 2023; 141: 567-578.","DOI":"10.1182\/blood.2022017865"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Cheng W, Yu TT, Tang AP, He Young K, Yu L. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches. Curr Med Sci. 2021; 41: 405-419.","DOI":"10.1007\/s11596-021-2393-3"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Sapienza MR, Pileri S. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics. Hematol Oncol Clin North Am. 2020; 34: 511-521.","DOI":"10.1016\/j.hoc.2020.01.002"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Sapienza MR, Pileri A, Derenzini E <i>et al.<\/i> Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects. Cancers (Basel). 2019; 11: 595.","DOI":"10.3390\/cancers11050595"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Julia F, Dalle S, Duru G <i>et al.<\/i> Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014; 38: 673-680.","DOI":"10.1097\/PAS.0000000000000156"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Laribi K, Baugier de Materre A, Sobh M <i>et al.<\/i> Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv. 2020; 4: 4838-4848.","DOI":"10.1182\/bloodadvances.2020002474"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Taylor J, Haddadin M, Upadhyay VA <i>et al.<\/i> Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019; 134: 678-687.","DOI":"10.1182\/blood.2019001144"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Feuillard J, Jacob MC, Valensi F <i>et al.<\/i> Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002; 99: 1556-1563.","DOI":"10.1182\/blood.V99.5.1556"},{"key":"62","unstructured":"62 Garnache-Ottou F, Vidal C, Biichl\u00e9 S <i>et al.<\/i> How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? Blood Adv. 2019; 3: 4238-4251."},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Jegalian AG, Buxbaum NP, Facchetti F <i>et al.<\/i> Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010; 95: 1873-1879.","DOI":"10.3324\/haematol.2010.026179"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Tsagarakis NJ, Kentrou NA, Papadimitriou KA <i>et al.<\/i> Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res. 2010; 34: 438-446.","DOI":"10.1016\/j.leukres.2009.09.006"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Pemmaraju N, Lane AA, Sweet KL <i>et al.<\/i> Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019; 380: 1628-1637.","DOI":"10.1056\/NEJMoa1815105"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Roos-Weil D, Dietrich S, Boumendil A <i>et al.<\/i> Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013; 121: 440-446.","DOI":"10.1182\/blood-2012-08-448613"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Rauh MJ, Rahman F, Good D <i>et al.<\/i> Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. Leuk Res. 2012; 36: 81-86.","DOI":"10.1016\/j.leukres.2011.07.033"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Pagano L, Valentini CG, Pulsoni A <i>et al.<\/i> Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013; 98: 239-246.","DOI":"10.3324\/haematol.2012.072645"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Mart\u00edn-Mart\u00edn L, Almeida J, Pomares H <i>et al.<\/i> Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016; 7: 10174-10181.","DOI":"10.18632\/oncotarget.7101"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Pemmaraju N, Wilson NR, Khoury JD <i>et al.<\/i> Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021; 138: 1373-1377.","DOI":"10.1182\/blood.2021011817"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Khoury JD, Medeiros LJ, Manning JT <i>et al.<\/i> CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer. 2002; 94: 2401-2408.","DOI":"10.1002\/cncr.10489"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Pemmaraju N, Wilson NR, Garcia-Manero G <i>et al.<\/i> Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022; 6: 3027-3035.","DOI":"10.1182\/bloodadvances.2021006645"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Yun S, Chan O, Kerr D <i>et al.<\/i> Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Adv. 2020; 4: 3435-3442.","DOI":"10.1182\/bloodadvances.2020001875"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Bashir Q, Milton DR, Popat UR <i>et al.<\/i> Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant. 2022; 57: 51-56.","DOI":"10.1038\/s41409-021-01478-5"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013; 19: 1006-1012.","DOI":"10.1016\/j.bbmt.2013.01.027"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Kharfan-Dabaja MA, Al Malki MM, Deotare U <i>et al.<\/i> Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017; 179: 781-789.","DOI":"10.1111\/bjh.14954"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Bruch PM, Dietrich S, Finel H <i>et al.<\/i> Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters. Leukemia. 2023; 37: 465-472.","DOI":"10.1038\/s41375-022-01782-z"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Aoki T, Suzuki R, Kuwatsuka Y <i>et al.<\/i> Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015; 125: 3559-3562.","DOI":"10.1182\/blood-2015-01-621268"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Murthy HS, Zhang MJ, Chen K <i>et al.<\/i> Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis. Blood Adv. 2023; 7: 7007-7016.","DOI":"10.1182\/bloodadvances.2023011308"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Pemmaraju N, Sweet KL, Stein AS <i>et al.<\/i> Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022; 40: 3032-3036.","DOI":"10.1200\/JCO.22.00034"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Daver NG, Montesinos P, DeAngelo DJ <i>et al.<\/i> Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024; 25: 388-399.","DOI":"10.1016\/S1470-2045(23)00674-5"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Montero J, Stephansky J, Cai T <i>et al.<\/i> Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017; 7: 156-164.","DOI":"10.1158\/2159-8290.CD-16-0999"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Gangat N, Konopleva M, Patnaik MM <i>et al.<\/i> Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2022; 97: E62-E67.","DOI":"10.1002\/ajh.26417"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Piccini M, Loscocco GG, Gianfaldoni G <i>et al.<\/i> Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm. Ann Hematol. 2020; 99: 907-909.","DOI":"10.1007\/s00277-020-03939-1"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Pemmaraju N, Wilson NR, Senapati J <i>et al.<\/i> CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res. 2022; 121: 106928.","DOI":"10.1016\/j.leukres.2022.106928"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Sakamoto K, Baba S, Okumura Y <i>et al.<\/i> Comparison and Development of Immunohistochemical Diagnostic Criteria for Blastic Plasmacytoid Dendritic Cell Neoplasm. Mod Pathol. 2023; 36: 100253.","DOI":"10.1016\/j.modpat.2023.100253"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Pulford K, Banham AH, Lyne L <i>et al.<\/i> The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells. Leukemia. 2006; 20: 1439-1441.","DOI":"10.1038\/sj.leu.2404260"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88 Montes-Moreno S, Ramos-Medina R, Mart\u00ednez-L\u00f3pez A <i>et al.<\/i> SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood. 2013; 121: 643-647.","DOI":"10.1182\/blood-2012-08-447599"},{"key":"89","unstructured":"89 Knowles DM, Orazi A, Foucar K, Weiss LM. Knowles\u2019 neoplastic hematopathology. 3rd ed ed: Wolters Kluwer, Lippincott Williams &amp; Wilkins; 2014."},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Tang H, Panse G, Braddock D <i>et al.<\/i> IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. J Cutan Pathol. 2023; 50: 595-600.","DOI":"10.1111\/cup.14439"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Reichard KK, Burks EJ, Foucar MK <i>et al.<\/i> CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol. 2005; 29: 1274-1283.","DOI":"10.1097\/01.pas.0000172194.32918.5c"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 Wu SJ, Sadigh S, Lane AA, Pinkus GS. Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. Am J Clin Pathol. 2023; 159: 455-463.","DOI":"10.1093\/ajcp\/aqac174"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Togami K, Pastika T, Stephansky J <i>et al.<\/i> DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019; 129: 5005-5019.","DOI":"10.1172\/JCI128571"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Wang W, Khoury JD, Miranda RN <i>et al.<\/i> Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021; 106: 1047-1055.","DOI":"10.3324\/haematol.2020.247569"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Garnache-Ottou F, Feuillard J, Ferrand C <i>et al.<\/i> Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009; 145: 624-636.","DOI":"10.1111\/j.1365-2141.2009.07679.x"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Cota C, Vale E, Viana I <i>et al.<\/i> Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010; 34: 75-87.","DOI":"10.1097\/PAS.0b013e3181c5e26b"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Ceribelli M, Hou ZE, Kelly PN <i>et al.<\/i> A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Cell. 2016; 30: 764-778.","DOI":"10.1016\/j.ccell.2016.10.002"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Sukswai N, Aung PP, Yin CC <i>et al.<\/i> Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol. 2019; 43: 1429-1437.","DOI":"10.1097\/PAS.0000000000001316"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ. CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom. 2009; 76: 237-248.","DOI":"10.1002\/cyto.b.20469"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Cronin DM, George TI, Reichard KK, Sundram UN. Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm. Am J Clin Pathol. 2012; 137: 367-376.","DOI":"10.1309\/AJCP9IS9KFSVWKGH"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Roussel X, Garnache Ottou F, Renosi F. Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms. Cancers (Basel). 2022; 14: 3545.","DOI":"10.3390\/cancers14143545"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 MacDonald KP, Munster DJ, Clark GJ <i>et al.<\/i> Characterization of human blood dendritic cell subsets. Blood. 2002; 100: 4512-4520.","DOI":"10.1182\/blood-2001-11-0097"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103 McQuaid DC, Panse G, Wang WL <i>et al.<\/i> Global assessment of IRF8 as a novel cancer biomarker. Hum Pathol. 2022; 122: 1-10.","DOI":"10.1016\/j.humpath.2022.01.004"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104 B\u00e9net C, Gomez A, Aguilar C <i>et al.<\/i> Histologic and immunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. Am J Clin Pathol. 2011; 135: 278-290.","DOI":"10.1309\/AJCPFMNYCVPDEND0"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105 Sangle NA, Schmidt RL, Patel JL <i>et al.<\/i> Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol. 2014; 27: 1137-1143.","DOI":"10.1038\/modpathol.2013.238"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Valentini CG, Piciocchi A, Facchetti F <i>et al.<\/i> Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey. Blood Adv. 2021; 5: 5608-5611.","DOI":"10.1182\/bloodadvances.2021005802"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107 El Hussein S, Wang W. Flow Cytometry Profiling of Plasmacytoid Dendritic Cell Neoplasms. Cancers (Basel). 2024; 16: 2118.","DOI":"10.3390\/cancers16112118"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108 Tansey WP. Mammalian MYC Proteins and Cancer. New Journal of Science. 2014; 2014: 1-27.","DOI":"10.1155\/2014\/757534"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109 Fu Y, Fesler M, Mahmud G <i>et al.<\/i> Narrowing down the common deleted region of 5q to 6.0 Mb in blastic plasmacytoid dendritic cell neoplasms. Cancer Genet. 2013; 206: 293-298.","DOI":"10.1016\/j.cancergen.2013.07.002"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110 Momoi A, Toba K, Kawai K <i>et al.<\/i> Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases. Leuk Res. 2002; 26: 693-698.","DOI":"10.1016\/S0145-2126(01)00198-9"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111 Maeda T, Murata K, Fukushima T <i>et al.<\/i> A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol. 2005; 81: 148-154.","DOI":"10.1532\/IJH97.04116"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112 Takiuchi Y, Maruoka H, Aoki K <i>et al.<\/i> Leukemic manifestation of blastic plasmacytoid dendritic cell neoplasm lacking skin lesion: a borderline case between acute monocytic leukemia. J Clin Exp Hematop. 2012; 52: 107-111.","DOI":"10.3960\/jslrt.52.107"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113 Nakamura Y, Kayano H, Kakegawa E <i>et al.<\/i> Identification of SUPT3H as a novel 8q24\/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation. Blood Cancer J. 2015; 5: e301.","DOI":"10.1038\/bcj.2015.26"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114 Tzankov A, Hebeda K, Kremer M <i>et al.<\/i> Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow: Summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European Bone Marrow Working Group, Basel 2016. Ann Hematol. 2017; 96: 765-777.","DOI":"10.1007\/s00277-017-2947-4"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115 Boddu PC, Wang SA, Pemmaraju N <i>et al.<\/i> 8q24\/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. Leuk Res. 2018; 66: 73-78.","DOI":"10.1016\/j.leukres.2018.01.013"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116 Sumarriva Lezama L, Chisholm KM, Carneal E <i>et al.<\/i> An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality. Histopathology. 2018; 73: 767-776.","DOI":"10.1111\/his.13668"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117 Kurt H, Khoury JD, Medeiros LJ, Huh YO. Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations. Br J Haematol. 2018; 181: 305.","DOI":"10.1111\/bjh.15128"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118 Hammond DW, Goepel JR, Aitken M <i>et al.<\/i> Cytogenetic analysis of a United Kingdom series of non-Hodgkins lymphomas. Cancer Genet Cytogenet. 1992; 61: 31-38.","DOI":"10.1016\/0165-4608(92)90366-G"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119 Harrison CJ, Mazzullo H, Cheung KL <i>et al.<\/i> Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results. Br J Haematol. 2003; 120: 944-952.","DOI":"10.1046\/j.1365-2141.2003.04172.x"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120 Rack K, Vidrequin S, Dargent JL. Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases. J Clin Pathol. 2016; 69: 82-86.","DOI":"10.1136\/jclinpath-2015-203054"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121 Ohanian M, Bueso-Ramos C, Ok CY <i>et al.<\/i> Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015; 208: 571-574.","DOI":"10.1016\/j.cancergen.2015.06.004"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122 Tang G, Hu S, Wang SA <i>et al.<\/i> t(3;8)(q26.2;q24) Often Leads to MECOM\/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and\/or Disease Progression. J Mol Diagn. 2019; 21: 343-351.","DOI":"10.1016\/j.jmoldx.2018.10.005"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123 Kubota S, Tokunaga K, Umezu T <i>et al.<\/i> Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm. Nat Commun. 2019; 10: 1653.","DOI":"10.1038\/s41467-019-09710-z"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124 Suzuki K, Suzuki Y, Hama A <i>et al.<\/i> Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2017; 31: 1629-1633.","DOI":"10.1038\/leu.2017.101"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125 Kosasih HJ, Healey G, Brennan MS <i>et al.<\/i> A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax. Hemasphere. 2024; 8: e1.","DOI":"10.1002\/hem3.1"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126 Brayer KJ, Frerich CA, Kang H, Ness SA. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. Cancer Discov. 2016; 6: 176-187.","DOI":"10.1158\/2159-8290.CD-15-0859"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127 Lahortiga I, De Keersmaecker K, Van Vlierberghe P <i>et al.<\/i> Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007; 39: 593-595.","DOI":"10.1038\/ng2025"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128 Liu Y, Easton J, Shao Y <i>et al.<\/i> The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017; 49: 1211-1218.","DOI":"10.1038\/ng.3909"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129 Shirazi PT, Eadie LN, Heatley SL <i>et al.<\/i> Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia. Cancer Gene Ther. 2022; 29: 1140-1152.","DOI":"10.1038\/s41417-021-00421-6"},{"key":"130","doi-asserted-by":"crossref","unstructured":"130 Quelen C, Lippert E, Struski S <i>et al.<\/i> Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. Blood. 2011; 117: 5719-5722.","DOI":"10.1182\/blood-2011-01-333013"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131 Iacobucci I, Wen J, Meggendorfer M <i>et al.<\/i> Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019; 51: 694-704.","DOI":"10.1038\/s41588-019-0375-1"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132 Belloni E, Shing D, Tapinassi C <i>et al.<\/i> In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. Leukemia. 2011; 25: 733-736.","DOI":"10.1038\/leu.2010.317"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133 Petrella T, Facchetti F. Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009? Autoimmunity. 2010; 43: 210-214.","DOI":"10.3109\/08916930903510898"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134 Vermi W, Facchetti F, Rosati S <i>et al.<\/i> Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes\/interferon-producing cells associated with myeloid disorders. Am J Surg Pathol. 2004; 28: 585-595.","DOI":"10.1097\/00000478-200405000-00004"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135 Vitte F, Fabiani B, B\u00e9net C <i>et al.<\/i> Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol. 2012; 36: 1302-1316.","DOI":"10.1097\/PAS.0b013e31825dd4de"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136 Vuckovic S, Fearnley DB, Gunningham S <i>et al.<\/i> Dendritic cells in chronic myelomonocytic leukaemia. Br J Haematol. 1999; 105: 974-985.","DOI":"10.1046\/j.1365-2141.1999.01431.x"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137 Orazi A, Chiu R, O\u2019Malley DP <i>et al.<\/i> Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol. 2006; 19: 1536-1545.","DOI":"10.1038\/modpathol.3800707"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138 Lucas N, Duchmann M, Rameau P <i>et al.<\/i> Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019; 33: 2466-2480.","DOI":"10.1038\/s41375-019-0447-3"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139 Deng C, Gao B, Wang T <i>et al.<\/i> T Lymphoblastic Lymphoma Hiding in Mature Plasmacytoid Dendritic Cell Proliferation: A Case Report and Literature Review. Diagnostics (Basel). 2023; 13: 3248.","DOI":"10.3390\/diagnostics13203248"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140 Fei F, Liedtke M, Silva O. Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid Neoplasm. Front Oncol. 2022; 12: 903113.","DOI":"10.3389\/fonc.2022.903113"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141 Machan S, Alonso-Dominguez JM, S\u00e1nchez Garc\u00eda FJ <i>et al.<\/i> Plasmacytoid Dendritic Cell Dermatosis Associated to Myeloproliferative\/Myelodysplastic Neoplasms. Am J Surg Pathol. 2022; 46: 1623-1632.","DOI":"10.1097\/PAS.0000000000001960"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142 Mah\u00e9vas T, Osio A, Larcher L <i>et al.<\/i> Cutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms. Blood Adv. 2024; 8: 3293-3298.","DOI":"10.1182\/bloodadvances.2023012489"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143 Chen Y-C, Chou J-M, Ketterling RP, Letendre L, Li C-Y. Histologic and immunohistochemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am J Clin Pathol. 2003; 120: 874-881.","DOI":"10.1309\/UNM9TY9QJQNFFYTH"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144 Pileri SA, Ascani S, Cox MC <i>et al.<\/i> Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007; 21: 340-350.","DOI":"10.1038\/sj.leu.2404491"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145 Khellaf M, Michel M, Quittet P <i>et al.<\/i> Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011; 118: 4338-4345.","DOI":"10.1182\/blood-2011-03-340166"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146 Rickmann M, Krauter J, Stamer K <i>et al.<\/i> Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol. 2011; 90: 1047-1058.","DOI":"10.1007\/s00277-011-1231-2"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147 Mohty M, Jarrossay D, Lafage-Pochitaloff M <i>et al.<\/i> Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood. 2001; 98: 3750-3756.","DOI":"10.1182\/blood.V98.13.3750"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148 Xiao W, Chan A, Waarts MR <i>et al.<\/i> Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021; 137: 1377-1391.","DOI":"10.1182\/blood.2020007897"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149 Zalma\u00ef L, Viailly PJ, Biichle S <i>et al.<\/i> Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica. 2021; 106: 3056-3066.","DOI":"10.3324\/haematol.2020.253740"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150 Wang W, Xu J, Khoury JD <i>et al.<\/i> Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2022; 14: 3375.","DOI":"10.3390\/cancers14143375"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151 Hamadeh F, Awadallah A, Meyerson HJ, Beck RC. Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation. Cytometry B Clin Cytom. 2020; 98: 43-51.","DOI":"10.1002\/cyto.b.21761"},{"key":"152","doi-asserted-by":"crossref","unstructured":"152 Huang Y, Wang Y, Chang Y <i>et al.<\/i> Myeloid Neoplasms with Elevated Plasmacytoid Dendritic Cell Differentiation Reflect the Maturation Process of Dendritic Cells. Cytometry A. 2020; 97: 61-69.","DOI":"10.1002\/cyto.a.23953"},{"key":"153","doi-asserted-by":"crossref","unstructured":"153 Mart\u00edn-Mart\u00edn L, Almeida J, Hern\u00e1ndez-Campo PM <i>et al.<\/i> Immunophenotypical, morphologic, and functional characterization of maturation-associated plasmacytoid dendritic cell subsets in normal adult human bone marrow. Transfusion. 2009; 49: 1692-1708.","DOI":"10.1111\/j.1537-2995.2009.02170.x"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24069\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:50:29Z","timestamp":1743209429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24069\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":153,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24069","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"24069"}}